Gene Expression Patterns That Characterize Advanced Stage Serous Ovarian Cancers
Authors:
- Holly K. DressmanHDHolly K. Dressman
- Regina S. WhitakerRWRegina S. Whitaker
- Laura HavrileskyLHLaura Havrilesky
- Jonathan GrayJGJonathan Gray
- Jeffrey R. MarksJMJeffrey R. Marks
- 1 January 2004
- journal article
- Published by Springer Nature in Journal of the Society for Gynecologic Investigation
- Vol. 11 (1) , 51-59
Abstract
To identify gene expression patterns that characterize advanced stage serous ovarian cancers by using microarray expression analysis. Using genome-wide expression analysis, we compared a series of 31 advanced stage (III or IV) serous ovarian cancers from patients who survived either less than 2 years or more than 7 years with three normal ovarian epithelial samples. Array findings were validated by analysis of expression of the insulin-like growth factor binding protein 2 (IGFBP2) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) genes using quantitative real-time polymerase chain reaction (QRT-PCR). Hierarchical clustering identified patterns of gene expression that distinguished cancer from normal ovarian epithelium. We also identified gene expression patterns that distinguish cancers on the basis of patient survival. These genes include many that are associated with immune function. Expression of IGFBP2 and TRAIL genes measured by array and QRT-PCR analysis demonstrated correlation coefficients of 0.63 and 0.78, respectively. Global expression analysis can identify expression patterns and individual genes that contribute to ovarian cancer development and outcome. Many of the genes that determine ovarian cancer survival are associated with the immune response, suggesting that immune function influences ovarian cancer virulence. With the generation of newer arrays with more transcripts, larger studies are possible to fully characterize genetic signatures that predict survival that may ultimately be used to guide therapeutic decision-making.Keywords
This publication has 14 references indexed in Scilit:
- Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian CancersJNCI: Journal of the National Cancer Institute, 2002
- Loss of Expression of the p16 Tumor Suppressor Gene Is More Frequent in Advanced Ovarian Cancers Lacking p53 MutationsGynecologic Oncology, 2001
- Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancerProceedings of the National Academy of Sciences, 2001
- p21 (WAF1/CIP1) Protein Expression Is Associated with Prolonged Survival but Not with p53 Expression in Epithelial Ovarian CarcinomaGynecologic Oncology, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancerOncogene, 1998
- The p53 tumor suppressor gene frequently is altered in gynecologic cancersAmerican Journal of Obstetrics and Gynecology, 1994
- The p53 tumor suppressor gene frequently is altered in gynecologic cancersAmerican Journal of Obstetrics and Gynecology, 1994
- Spectrum of Mutation and Frequency of Allelic Deletion of the p53 Gene in Ovarian CancerJNCI: Journal of the National Cancer Institute, 1993
- Regulation of growth of normal ovarian epithelial cells andovarian cancer cell lines by transforming growth factor-ßAmerican Journal of Obstetrics and Gynecology, 1992